Valuation: EyePoint, Inc.

Market Cap 2.66Cr 2.43Cr 2.24Cr 2.04Cr 3.82Cr 246.92Cr 4.02Cr 27Cr 11Cr 134.67Cr 10Cr 9.79Cr 423.3Cr P/E 2026 *
-0.06x
P/E 2027 * -0.14x
Enterprise Value -11Cr -10Cr -9.54Cr -8.66Cr -16Cr -1.05TCr -17Cr -115.63Cr -46Cr -572.89Cr -43Cr -42Cr -1.8TCr EV / Sales 2026 *
-53.6x
EV / Sales 2027 * -225x
Free-Float
97.33%
Yield 2026 *
-
Yield 2027 * -
1 day-11.36%
1 week-23.46%
Current month-32.78%
1 month-45.53%
3 months-95.60%
6 months-98.17%
Current year-98.72%
1 week 0.23
Extreme 0.2277
0.32
1 month 0.23
Extreme 0.2277
0.43
Current year 0.23
Extreme 0.2277
18.87
1 year 0.23
Extreme 0.2277
19.11
3 years 0.23
Extreme 0.2277
30.99
5 years 0.23
Extreme 0.2277
30.99
10 years 0.23
Extreme 0.2277
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Others

Chief Financial Officer

-1,39,906 0.1669%
18/08/26 Buy

Director

10,600 0.0126%
10/07/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-11.36%-23.46%-98.29%-96.17% 2.66Cr
-0.30%-6.68%+27.12%+127.32% 1,20000Cr
+1.25%-5.35%+32.65%+78.98% 65TCr
+0.94%-2.99%+21.13%+106.30% 51TCr
-0.60%-1.95%+25.73%+67.00% 38TCr
+0.69%-9.50%+36.78%+30.83% 33TCr
+0.41%-4.70%+24.18%+50.18% 29TCr
+0.81%-4.08%-2.95%+31.59% 27TCr
-0.15%-6.45%+29.06%+65.76% 24TCr
-0.06%-0.98%+31.42%+122.83% 21TCr
Average -0.84%-6.63%+12.68%+58.46% 41TCr
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%

Financials

2026 *2027 *
Net sales 21.16L 19.28L 17.79L 16.16L 30.33L 20Cr 31.89L 2.16Cr 85.87L 11Cr 79.37L 77.7L 34Cr 9L 8L 8L 7L 13.16L 8.51Cr 13.84L 93.64L 37.26L 4.64Cr 34.44L 33.72L 15Cr
Net income -34Cr -31Cr -28Cr -26Cr -48Cr -3.13TCr -51Cr -344.28Cr -136.99Cr -1.71TCr -126.63Cr -123.96Cr -5.36TCr -19Cr -18Cr -16Cr -15Cr -28Cr -1.79TCr -29Cr -196.56Cr -78Cr -973.86Cr -72Cr -71Cr -3.06TCr
Net Debt -14Cr -13Cr -12Cr -11Cr -20Cr -1.3TCr -21Cr -142.81Cr -57Cr -707.56Cr -53Cr -51Cr -2.22TCr -23Cr -21Cr -20Cr -18Cr -33Cr -2.16TCr -35Cr -237.75Cr -95Cr -1.18TCr -87Cr -86Cr -3.7TCr
Projected Income Statement - Annual - EyePoint, Inc.
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
20/26/20 $0.2342 -11.36% 49,38,937
19/26/19 $0.2642 -2.87% 34,47,525
18/26/18 $0.2720 -8.08% 36,10,328
17/26/17 $0.2959 -3.80% 45,76,326
16/26/16 $0.3076 +0.52% 65,46,986
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - EyePoint, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
0.2342USD
Average target price
8.312USD
Spread / Average Target
+3,449.32%
  1. Stock Market
  2. Stocks
  3. EYPT Stock
BLACK FRIDAY -Get 40% off all subscriptions
BLACK FRIDAY40% off all subscriptions
Get the offer